Prognostic assay for squamous cell lung carcinoma
US11208690B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 23, 2019 |
| Grant date | Dec 28, 2021 |
| Priority date | — |
| Expiry date | Sep 23, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Methods for predicting clinical outcome for a human subject diagnosed with squamous cell lung carcinoma using a panel of molecular markers that includes CDKN2A and CCND1. The markers are related to the subject's increased likelihood of a negative clinical outcome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.